Regal and Eli Lilly join hands in the industry: License-out projects for Chinese pharmaceutical companies will become increasingly popular

 With the reform of China's pharmaceutical policy, innovation has become the main theme
.
In recent years, under the advancement of medical reform and drug reform, the license-in and license-out of pharmaceutical companies have become hot, and they have gradually become a trend
.
The author was informed that there was another news of cooperation between a domestic pharmaceutical company and a multinational pharmaceutical company recently
.
That is, Shanghai Rich Pharmaceuticals has reached a cooperation with the multinational pharmaceutical company Eli Lilly.
The two parties will cooperate closely in the development of preclinical drugs, clinical research and commercialization in the next few years, and jointly develop innovative therapies for the field of metabolic diseases
.
According to the terms of the agreement, Rieger Pharmaceuticals will grant Eli Lilly an intellectual property license, and Eli Lilly may choose to extend the license
.
Eli Lilly will be responsible for clinical development, production and commercialization outside of Greater China
.
In addition, Eli Lilly will pay up to 50 million U.
S.
dollars in advance (part of equity investment), Rige Pharmaceuticals is also eligible for future milestone payments of up to 1.
5 billion U.
S.
dollars in potential futures, as well as the use of tiered franchise rights for product net sales.
Fee
.
The person in charge of Ruige Pharmaceutical said that this cooperation is the recognition of the core technology and research capabilities of Ruige Pharmaceutical by Eli Lilly
.
Relevant persons from Eli Lilly in the United States also said that the cooperation with Rege Pharmaceuticals will help Eli Lilly further accelerate innovative research in the field of diabetes and weight loss, and find more breakthrough therapies
.
According to the industry, if License-in is the hard currency that drives the development of China's innovative drug industry, then License-out is the stepping stone for Chinese innovative drug companies to successfully "go global" and go international
.
It is understood that in addition to the aforementioned license-out events, the license-outs of companies such as Baiji, Cinda, Jacos, and Rongchang Biotechnology have all brought tens of millions of dollars and hundreds of millions of dollars in milestone benefits
.
The author was informed that there were also multiple license out transactions in November
.
For example, on November 10, Luye Pharma announced that it has reached a cooperation with Zambon Switzerland, granting Zambon Switzerland the right to commercialize the Mindo Day transdermal patch in Liss in Switzerland
.
It is reported that Liszmin's transdermal patch is an innovative patch formulation of Liszmin twice a week for the treatment of mild to moderate dementia related to Alzheimer's disease
.
The product was developed by Luye Pharma’s proprietary transdermal drug delivery technology platform and has been approved for marketing in many European countries
.
On November 30, Jimin Credential announced that its subsidiary Jiyu Pharmaceutical and Huya Biotechnology have reached an exclusive license agreement for the KRAS inhibitor JMKX1899
.
According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.
All
.
It is reported that JMKX1899 is a KRAS inhibitor independently developed by the Small Molecule Innovation Center of Jiyu Pharmaceutical.
Pre-clinical research data shows that JMKX1899 has stronger brain permeability compared with products with the same target, and there is no cardiotoxicity and drug-drug Interaction risk
.
Innovative research and development strength is recognized by the industry, and overseas authorization can speed up the pace of internationalization
.
With the continuous development of domestic innovative drugs, overseas authorization incidents continue to increase
.
For example, Shanghai Pharmaceuticals recently announced that it has signed a formal agreement with HUYABIO INTERNATIonAL ("HUYABIO") on "Shanghai Pharmaceuticals Licenses SPH6162 Overseas Rights and Interests to HUYABIO"
.
In this license-out cooperation, HUYABIO intends to pay a milestone payment of no more than US$292.
5 million plus a 3-6% sales commission to obtain the exclusive product development, production and sales of Shanghai Pharmaceutical’s new anti-tumor drug SPH6162 outside of China.
Authorization and the right to sublicense
.
Analysts said that in the future, there will be more and more license-out projects for Chinese pharmaceutical companies
.
"License-in is always buying, but there will always be fewer and fewer things to buy, but as long as the license-out is done, there will be more and more things.

.
In the future, the license-out of Chinese pharmaceutical companies will definitely be prosperous, and even exceed the license-in
.
"Now China's pharmaceutical industry is gradually moving toward the center of the world stage.
Whether it is license-in or license-out, international cooperation in medicine will become the new normal
.